Hyperpituitarism: Clinical Trials

6 trials for Hyperpituitarism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Terminated 6

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Paltusotine, Placebo - Acromegaly
Phase 3TerminatedCrinetics Pharmaceuticals Inc.1112021-12-172026-07-15
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Paltusotine, Placebo - Acromegaly
Phase 3TerminatedCrinetics Pharmaceuticals Inc.582021-05-122026-07-15
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Gallium-68 DOTATOC PET - Pituitary Tumours
Phase 3TerminatedGöteborg University222015-01-012022-03-31
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
Octreotide - Acromegaly
Phase 3TerminatedEndo USA Inc., a Keenova Therapeutics Company122011-02-012013-09-20
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Octreotide Implant, Sandostatin LAR Depot - Acromegaly
Phase 3TerminatedEndo USA Inc., a Keenova Therapeutics Company1692008-09-012013-09-27
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg - Acromegaly
Phase 3TerminatedAmbrilia Biopharma, Inc.402008-02-012010-02-09

Narrower conditions

Acromegaly (6)  ·  Pituitary Diseases (1)  ·  Pituitary Neoplasms (1)

Broader conditions

Bone Diseases (6)  ·  Bone Diseases, Endocrine (6)  ·  Brain Diseases (6)  ·  Central Nervous System Diseases (6)  ·  Endocrine System Diseases (6)  ·  Hypothalamic Diseases (6)  ·  Musculoskeletal Diseases (6)  ·  Nervous System Diseases (6)  ·  Pituitary Diseases (5)  ·  Brain Neoplasms (1)  ·  Central Nervous System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Hypothalamic Neoplasms (1)  ·  Neoplasms (1)

Interventions

Octreotide (3)

Sponsors

Crinetics Pharmaceuticals Inc. (2)  ·  Endo USA Inc., a Keenova Therapeutics Company (2)  ·  Ambrilia Biopharma, Inc. (1)  ·  Göteborg University (1)

Countries

United States (5)  ·  Hungary (4)  ·  Poland (3)  ·  Serbia (3)  ·  Argentina (2)  ·  Brazil (2)  ·  Bulgaria (2)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  Russia (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Belarus (1)

Top investigators

Raphael Naudin, M.D. (1)

Results publications

PMID 23969184